

# 2009 Fact Book

---

The information set forth in this publication is  
Compiled and amended annually by the budget and  
finance staff of the National Cancer Institute and is  
intended primarily for the use by members of the Institute  
and others involved in the administration and  
management of the National Cancer Program.  
Questions regarding any of the information contained  
Herein may be directed to the Office of Budget and  
Finance, National Cancer Institute, 9000 Rockville  
Pike, Bethesda, Maryland, 20892

# TABLE OF CONTENTS

---

<b>Executive Summary</b>	Fiscal Year 2009 Annual Report.....iii
<b>Organization</b>	Director's Biography ..... O-1A-B Former Directors of the NCI..... O-2 National Cancer Advisory Board..... O-3 Boards of Scientific Counselors and Advisors..... O-7 President's Cancer Panel ..... O-8 Executive Committee Members ..... O-8 NCI Director's Consumer Liaison Group..... O-9 Operational Organization Charts: National Cancer Institute ..... O-10 Office of the Director..... O-11 OD I: Office of Management ..... O-12 OD II: Center for Biomedical Informatics and Information Technology ..... O-13 OD II: Office of Science Planning and Assessment..... O-13 OD III: Office of Communications and Education ..... O-14 OD III: Office of Centers, Training and Resources ..... O-14 OD IV: Center to Reduce Cancer Health Disparities ..... O-15 OD IV: Center for Strategic and Scientific Initiatives ..... O-15 Center for Cancer Research..... O-16 Division of Cancer Biology..... O-18 Division of Cancer Epidemiology and Genetics..... O-19 Division of Cancer Prevention..... O-20 Division of Cancer Control and Population Sciences ..... O-21 Division of Cancer Treatment and Diagnosis ..... O-22 Division of Extramural Activities ..... O-23
<b>Cancer Statistics</b>	Links to Cancer Statistics ..... C-1
<b>Budget Data</b>	NCI Budget..... B-1 Program Structure ..... B-2 Extramural Funds ..... B-3 NCI Obligations by Mechanism..... B-4 Division Obligations by Mechanism ..... B-5 NIH Management Fund, Service & Supply Fund and GSA Rent.. B-6 Special Sources of Funds..... B-7 Funding for Various Research Areas ..... B-8
<b>Extramural Programs</b>	Research Project Grants: Number of Awards ..... E-1 Requested, Awarded ..... E-2 Awards by Activity Code ..... E-3 Activity Code Descriptions ..... E-4 Cancer Centers By State..... E-5 Specialized Programs of Research Excellence (SPORE) ..... E-6 National Research Service Awards – Pre and Post Doctoral Trainees ..... E-7

Construction/Renovation Funding.....	E-8
Grant and Contract Awards by State .....	E-9
Grant and Contract Awards by Country .....	E-10
Institutions Receiving More than \$15,000,000 in NCI Support ...	E-11

**Historical Trends**

Appropriations of the NCI .....	H-1
Bypass Budget Requests .....	H-2
Comparison of Bypass Requests and Appropriations of the NCI .	H-3
Comparison of Dollars, Positions and Space .....	H-4
Personnel Resources .....	H-5
AIDS Funding History .....	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Office of Budget and Finance homepage at <http://obf.cancer.gov/> on the National Cancer Institute's website: [www.nci.nih.gov](http://www.nci.nih.gov) or [www.cancer.gov](http://www.cancer.gov).

### Fiscal Year 2009 Annual Report

#### BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2009 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

#### Summary

Funds available to the NCI in FY 2009 totaled over \$4.967 billion, reflecting an increase of 3% and \$35 million from the previous fiscal year.

Fiscal highlights from FY 2009 include:

- Of the total NCI budget, 43% of the funds were allocated for Research Project Grants.
- The total number of Research Project Grants (RPGs) funded was 5,179. (includes SBIR)
- Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- 1,235 competing RPGs were funded.
- Almost one-third of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 16th percentile.
- 261 grants – totaling almost \$92 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research comprised almost 16% of the total NCI budget in FY 2009.
- Cancer Prevention & Control was eliminated as budget mechanism in FY2009

## **Distribution of the Budget by Funding Mechanism for FY 2008 and FY 2009**

### *Summary Points*

- The total budget for the Research Project Grant category increased by \$44 million.
- Funds for competing grants increased by \$2.5 million.
- Funds for training and career development of current and future research scientists through Research Career Awards remained stable.
- The total budget for Cancer Centers, Specialized Centers (U54) and SPORes increased by 18% due to the funding of two new Cancer Centers.
- Clinical Cooperative Groups and Community Clinical Oncology Program funds remained stable when you account for the shift from the Cancer Prevention and Control budget mechanism to the Clinical Cooperative Groups budget mechanism. Cancer Education funds increased by 6%.
- During FY 2009, NIH and DHHS Assessments increased by a total of \$26 million, including an increase of \$19.4 million for General Account and the Service and Supply Fund, \$4.2 million increase for Program Evaluation, and a \$2.4 million increase for the Management Fund.

**NCI Dollars by Mechanism for FY 2008 and 2009**  
(in thousands)

	2008	2009	Change '08-09	
			Am't	%
Research Project Grants:				
Noncompeting	\$1,517,375	\$1,550,906	33,531	2.2%
Admin Supplements	19,697	33,257	13,560	68.8%
Competing	455,348	457,834	2,486	0.5%
Subtotal, RPG	1,992,420	2,041,997	49,577	2.5%
SBIR/STTR	97,439	91,954	-5,485	-5.6%
Total, RPG	2,089,859	2,133,951	44,092	2.1%
Cancer Centers	274,470	313,713	39,243	14.3%
Specialized Cancer Centers (U54)	79,271	116,380	37,109	46.8%
SPOREs	123,293	131,360	8,067	6.5%
Total: Centers, Spec Ctrs, & SPOREs	477,034	561,453	84,419	17.7%
Research Career Program	79,528	79,120	-408	-0.5%
Cancer Education	30,089	31,945	1,856	6.2%
Clinical Cooperative Groups	143,975	234,531	90,556	62.9%
Other Grants	64,183	71,698	7,515	11.7%
Subtotal, Other	317,775	417,294	99,519	31.3%
Total, Research Grants	2,884,668	3,112,698	228,030	7.9%
National Research Service Awards	69,901	70,134	233	0.3%
R&D Contracts	444,189	610,142	165,953	37.4%
Intramural Research	718,372	781,389	63,017	8.8%
Research Management & Support	230,991	384,644	153,653	66.5%
Cancer Prevention & Control	471,515	0 *	-471,515	-100.0%
Construction	0	0	0	0.0%
Buildings and Facilities	7,920	7,920	0	0.0%
Total, NCI	4,827,556 *	4,966,927 **	139,371	2.9%
AIDS research included above	[258,499]	[265,882]	7,383	2.9%

\*Cancer Prevention and Control Eliminated as a Budget Mechanism in FY09.


\*\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

## Percent Share of Total NCI Dollars

### Summary Points

- The mechanism shares of the total budget have remained relatively stable from FY 2003 to FY 2009.

<b>Percent Share of Total NCI Dollars</b>					
	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>
<b>Research Project Grants</b>	45.6%	45.4%	44.1%	43.3%	43.0%
<b>Cancer Centers</b>	5.3%	5.6%	5.7%	5.7%	6.3%
<b>Specialized Centers</b>	1.4%	1.6%	1.6%	1.6%	2.3%
<b>SPOREs</b>	2.9%	2.6%	2.6%	2.6%	2.6%
<b>Clinical Cooperative Groups</b>	3.0%	3.1%	3.1%	3.0%	4.7%
<b>Intramural Research</b>	14.8%	14.5%	14.7%	14.9%	15.7%
<b>R&amp;D Contracts</b>	7.3%	7.3%	8.7%	9.2%	12.3%
<b>Cancer Prevention &amp; Control*</b>	11.1%	10.7%	10.4%	9.9%	0.0%
<b>Other Mechanisms</b>	8.7%	9.3%	9.2%	9.9%	3.7%





## Funding Trends

### Summary Points

- The NCI budget has increased by \$172.1 million – or 3.6% – since FY 2005.
- Intramural Research, Cancer Centers, Specialized Centers, SPORES, Clinical Cooperative Groups, and R&D Contracts have experienced percentage increases greater than the total NCI growth since FY 2004.

### Historical Funding Trends (Dollars in Millions)

	2005	2006	2007	2008	2009
<b>Total NCI</b>	\$4,794.8	\$4,747.2	\$4,792.6	\$4,827.6	\$4,966.9
<b>Research Project Grants</b>	2,188.9	2,156.9	2,111.8	2,089.9	2,134.0
<b>Intramural Research</b>	711.0	687.3	706.2	718.4	781.4
<b>Cancer Centers</b>	255.3	265.0	273.2	274.5	289.4
<b>Specialized Centers</b>	66.0	73.9	74.7	79.3	116.4
<b>SPORES</b>	133.0	124.9	123.8	123.3	155.7
<b>Clinical Cooperative Groups</b>	142.8	145.9	148.2	144.0	234.5
<b>Cancer Prevention &amp; Control</b>	531.6	505.6	498.4	471.5	0.0
<b>R&amp;D Contracts</b>	351.1	347.8	416.9	444.2	610.1
<b>Other Mechanisms</b>	415.1	439.8	439.4	482.5	645.5

### % Growth by Mechanism

	2005 to 2006	2006 to 2007	2007 to 2008	2008 to 2009	2005 to 2009
<b>Total NCI</b>	-1.0%	1.0%	0.7%	2.9%	3.6%
<b>Research Project Grants</b>	-1.5%	-2.1%	-1.0%	2.1%	-2.6%
<b>Intramural Research</b>	-3.3%	2.7%	1.7%	8.8%	9.9%
<b>Cancer Centers</b>	3.8%	3.1%	0.5%	5.4%	13.4%
<b>Specialized Centers</b>	12.0%	1.0%	6.2%	46.8%	76.3%
<b>SPORES</b>	-6.1%	-0.9%	-0.4%	26.2%	17.0%
<b>Clinical Cooperative Groups</b>	2.2%	1.6%	-2.8%	62.9%	64.2%
<b>Cancer Prevention &amp; Control</b>	-4.9%	1.4%	-5.4%	-100.0%	-100.0%
<b>R&amp;D Contracts</b>	-0.9%	19.9%	6.6%	6.6%	73.8%
<b>Other Mechanisms</b>	6.0%	-0.1%	9.8%	33.8%	55.5%

## Research Project Grants

### Summary Points

- 93% of competing dollars supported grants awarded within the established payline; 7% supported grants as an exception to the payline.
- RFA funds, which decreased from the FY 2008 dollar level, accounted for 11% of FY 2007 competing dollars.
- Research Project Grant applications submitted to NCI increased by approximately 3%.
- A total of 1,235 competing RPG's were funded.


### Research Project Grants (Dollars in Thousands)

	2008*		2009*	
	No.	Amount	No.	Amount
Total funding for RPGs	5,380	\$2,089,859	5,179	\$2,063,038
SBIR/STTR	312	\$97,439	261	\$91,954
Funding for RPGs without SBIR/STTR Program	5,068	\$1,992,420	4,918	\$1,971,084
Continuation or noncompeting grants funded				
Competing grants funded	1,266	\$455,348	1,235	\$457,834
Administrative Supplements	227	\$19,697	267	\$33,257
Partial assessment for DHHS Program Evaluation		\$68,382		\$70,912
Funds set aside within competing dollars for:				
Grants within Paylines:	1036	\$376,106	1,169	\$423,668
Traditional R01	586	\$219,267	680	\$259,819
Program Projects (P01)	23	\$42,929	23	\$39,339
RFA Grants	102	\$49,591	89	\$49,001
Share of competing grant funds		10.89%		10.70%
Exception Grants	230	\$79,242	66	\$34,165
Share of competing grant funds		17.40%		7.46%
Competing Application Requests	6,199	\$2,358,113	6,419	\$2,570,862
Funding Success Rate	20.2%		19.2%	
Percentile funding for R01 grants	14th		16th	
Average Cost-Competing		\$363		\$371
Average Reduction from recommended/requested levels		-17%		-17%

\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

## Grant Funding Paylines

RPG Mechanisms:	2008	2009	
R01 Traditional Grants	14th	16th	percentile
P01 Program Projects	N/A	N/A	priority score
R03 Small Grants	210	210	priority score
R21 Exploratory Phase I	14th	16th	percentile
R33 Exploratory Phase II	155	155	priority score
R41/R42 STTR	170	180	priority score
R43/R44 SBIR	245	210	priority score



**National Cancer Institute  
Extramural vs. Inhouse Funding**

(dollars in millions)


**Extramural**

<b>Mechanism</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>05-09% chg.</b>
Research Project Grants	\$2,188.9	\$2,156.9	\$2,111.8	\$2,089.9	\$2,134.0	-2.6%
Cancer Centers	255.3	265.0	273.2	274.5	314.2	23.1%
Specialized Centers	66.0	73.9	74.7	79.3	116.4	76.3%
SPOREs	133.0	124.9	123.8	123.3	130.9	-1.6%
Other Research Grants	309.0	327.1	322.9	317.8	417.3	35.0%
NRSA	67.3	66.6	68.2	69.9	70.1	4.2%
R&D Contracts	351.1	347.8	416.9	444.2	610.1	73.8%
Cancer Control Grants	232.0	213.5	200.1	190.4	0.0	-100.0%
Cancer Control Contracts	145.8	137.1	133.7	134.8	0.0	-100.0%
Construction	0	0	0	0	0	0.0%
Buildings & Facilities	8	7.9	7.9	7.9	7.9	100.0%
<b>Total Extramural Funds</b>	<b>3,756.3</b>	<b>3,720.7</b>	<b>3,733.2</b>	<b>3,732.0</b>	<b>3,800.9</b>	<b>1.2%</b>

**Inhouse**

<b>Mechanism</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>05-09% chg.</b>
Intramural Research	\$711.0	\$687.3	\$706.2	\$718.4	\$781.4	9.9%
RMS	173.7	184.1	188.7	231.0	384.6	121.4%
Control Inhouse	154.0	155.0	164.5	146.3	0.0	-100.0%
<b>Total Inhouse Funds</b>	<b>1,038.7</b>	<b>1,026.5</b>	<b>1,059.4</b>	<b>1,095.7</b>	<b>1,166.0</b>	<b>12.3%</b>

<b>Total NCI</b>	<b>4,795.0</b>	<b>4,747.2</b>	<b>4,792.6</b>	<b>4,827.7</b>	<b>4,966.9</b>	<b>3.6%</b>
------------------	----------------	----------------	----------------	----------------	----------------	-------------



## Research Career Awards – “K” Program


### Summary Points

- The Research Career Award mechanism decreased by .51% in FY 2009.
- The number of Research Career Awards decreased by 26 between FY 2008 and FY 2009.
- NCI funded 46 awards for the new NIH Pathway to Independence program.

(Dollars in Thousands)

		<b>2008</b>		<b>2009</b>	
		<b>No.</b>	<b>Amount</b>	<b>No.</b>	<b>Amount</b>
K01	Temin Awards	54	8,103	47	7,170
K01	Minority Mentored Career Development Award	48	6,528	49	6,577
	Subtotal, K01s	102	14,631	96	13,747
K05	Research Scientist Award	20	2,813	20	2,926
K07	Preventive Oncology	104	13,775	108	14,585
K08	Clinical Investigator	95	12,715	85	11,779
K12	Institutional Clinical Oncology Research	16	9,572	17	11,643
K22	Transition Career Development	47	7,284	43	6,763
K23	Patient-Oriented Career	48	6,453	44	6,178
K24	Patient-Oriented Career -- Mid Career	20	3,251	18	2,916
K25	Mentored Quantitative Research Career Development Award	21	2,881	22	3,087
K30	Institutional Curriculum Awards -- Administered by NCRR	0	0	0	0
K99	NIH Pathway to Independence Awards	52	6,153	46	5,496
	Total Research Career Program	525	79,528	499	79,120

**National Cancer Institute**  
FY 2009  
% of Total Research Award Funds



## Research Dollars by Various Cancers

### Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget

Research Dollars by Various Cancers  
(Dollars in Millions)

	2005	2006	2007	2008	2009
Total NCI	\$4,794.7	\$4,747.2	\$4,792.6	\$4,827.6	\$4,966.9
AIDS	265.9	253.7	253.7	258.5	265.9
Brain & Central Nervous System	124.9	130.3	148.2	153.7	151.5
Breast Cancer	560.1	584.7	572.4	586.8	599.4
Cervical Cancer	81.7	83.3	82.4	76.8	70.8
Clinical Trials	781.8	822.3	843.7	853.2	882.8
Colorectal Cancer	253.1	244.1	258.4	273.7	264.1
Head and Neck	89.5	71.3	66.2	76.1	76.8
Hodgkin's Disease	17.2	20.9	16.5	17.5	18.2
Leukemia	220.6	223.5	205.5	216.4	220.5
Liver Cancer	60.5	62.7	67.7	74.2	69.0
Lung Cancer	266.1	242.9	226.9	247.6	246.7
Melanoma	102.9	108.0	97.7	110.8	103.7
Multiple Myeloma	28.2	30.3	32.3	41.5	45.2
Non Hodgkin's Lymphoma	107.0	114.1	113.0	122.6	131.3
Ovarian Cancer	97.7	95.1	96.9	100.0	110.1
Pancreatic Cancer	66.7	74.2	73.3	87.3	89.6
Prostate Cancer	309.0	293.2	296.1	285.4	285.1
Stomach Cancer	11.0	11.5	12.0	12.4	15.4
Uterine Cancer	31.1	19.4	16.6	17.1	18.0

## 2009 and 2010 NCI American Recovery and Reinvestment Act (ARRA)

### Spending by Mech

(dollars in thousands)

	2009		2010
	No.	Amount	Amount
Research Project Grants:			
Noncompeting	-	-	
Admin Supplements	487	141,375	
Competing	543	230,825	
Subtotal, RPG	1030	372,200	
SBIR/STTR	1	6,906	
Total, RPG	1031	379,106	
Cancer Centers	-	-	
Specialized Cancer Centers (U54)	21	97,083	
SPOREs	-	-	
Total: Centers, Spec Ctrs, & SPOREs	21	97,083	
Research Career Program	-	11,360	
Cancer Education	1	1,292	
Clinical Cooperative Groups	-	19,821	
Other Grants	1	11,201	
Subtotal, Other	2	43,674	
Total, Research Grants	1054	519,863	
National Research Service Awards	10	1,109	
R&D Contracts	-	318,458	
Intramural Research	-	143	
Research Management & Support	-	6,023	
Total, NCI	1064	845,596	410,921

**Total ARRA Amount      1,256,517**

NCI received \$1.256 billion in American Recovery and Reinvestment Act (ARRA) funds to be distributed during the two year span of FY 2009 and FY 2010. ARRA dictates that NCI fund programs that preserve and create jobs and promote economic recovery, assist those most impacted by the recession, and provide investments to increase economic efficiency by spurring technological advances in science and health. Working under these parameters, the following programs of note are receiving ARRA funds through NCI:

- Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) – Funding 37 promising clinical trials of molecularly-targeted therapies to speed the delivery of personalized cancer treatments to patients.
- Cancer Centers Programs – 62 NCI designated Cancer Centers across the country received \$63 million in ARRA funding to supplement Cancer Center Support Grants.
- Personalized Cancer Care / Drug Development Platform – Enabling drug development that begins with the discovery of genetic changes and ends with targeted cancer therapies. Programs that support this vision include:
  - The Cancer Genome Atlas (TCGA) is developing a comprehensive catalog of genomic changes found in adult cancers;
  - Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is mapping the genetic changes associated with childhood cancers;
  - The Cancer Human Biobank (caHUB) leads quality biospecimen collection and management
  - The NCI Community Cancer Centers Program (NCCCP) involves patients around the country who provide data and volunteer for clinical trials.
- Physical Sciences in Oncology Centers – Exploring perspectives from the physical sciences to enhance our understanding of cancer biology.



# National Cancer Institute

---

## Director's Biography

### John E. Niederhuber, M.D.

John E. Niederhuber, M.D., became Director of the National Cancer Institute (NCI), one of the National Institutes of Health, in September 2006.

Throughout his distinguished career in academic medicine, Dr. Niederhuber has maintained ties to both NCI and the NIH. In addition to his work as a cancer surgeon, professor, laboratory investigator, department chair, medical school senior associate dean, associate dean for research, and university cancer center director, Dr. Niederhuber has also served as the Chair of the National Cancer Advisory Board, as an external NCI advisor and grant reviewer, and as a laboratory investigator supported by NCI and the NIH.

He joined NCI in a full-time capacity in September 2005, as Deputy Director for Translational and Clinical Sciences, and within a few weeks was asked to serve as Chief Operating Officer. He officially became NCI's Acting Director in June 2006. Since assuming the directorship of the NCI, Dr. Niederhuber has shaped the Nation's investment in cancer, to address areas that are likely to pay the largest health dividends. Together with Dr. Francis Collins, he began The Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging have benefited under his direction.

Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. As a leader of the National Cancer Program, he daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business, and the non-profit community dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.

In addition to his leadership of the NCI, Dr. Niederhuber heads his own Laboratory of Tumor and Stem Cell Biology in NCI's Center for Cancer Research and also holds a

## Thank You for previewing this eBook

You can read the full version of this eBook in different formats:

- HTML (Free /Available to everyone)
- PDF / TXT (Available to V.I.P. members. Free Standard members can access up to 5 PDF/TXT eBooks per month each month)
- Epub & Mobipocket (Exclusive to V.I.P. members)

To download this full book, simply select the format you desire below

